Healthcare > Pharmaceuticals & Biotechnology
•770 stocks
•
Total Market Cap: Loading...
Market Cap Distribution
Price Performance Heatmap
5Y Price (Market Cap Weighted)
All Stocks (770)
%
| Company | Market Cap | Price |
|---|---|---|
|
HIHO operates as an OEM/ODM contract manufacturer providing integrated manufacturing and subassembly services.
|
$7.35M |
$1.67
+1.21%
|
|
CBIO directly develops oncology-focused biologic therapies, aligning with the Biotech - Oncology category.
|
$7.32M |
$11.35
-6.81%
|
|
The company reports meaningful contract manufacturing demand growth, indicating it provides contract manufacturing services for diagnostics.
|
$7.20M |
$2.83
-4.07%
|
|
Cellectar directly develops radiopharmaceuticals and radioconjugates for cancer therapy, including its lead iopofosine I-131 and next-generation radiopharmaceuticals.
|
$7.13M |
$4.64
-3.73%
|
|
SBFM operates a Canadian generic prescription drug business (Nora Pharma) with multiple marketed generic drugs, making generic drugs a core revenue driver.
|
$7.06M |
$1.55
-6.63%
|
|
Core business: BioCardia's lead programs CardiAMP and CardiALLO are autologous/allogeneic cell therapies.
|
$7.04M |
$1.36
+0.37%
|
|
BETRF's pipeline includes BETR-001 and BETR-002, non-hallucinogenic neuroplastogens targeting mental health and anxiety-related disorders.
|
$7.04M |
$0.04
-6.38%
|
|
Core focus on CAR T and cell-based therapies (MB-101, MB-109) and oncolytic virus programs, i.e., cell therapy.
|
$6.92M |
$1.56
-0.95%
|
|
PMCB's core offering is oncology cell-based therapy using the Cell-in-a-Box encapsulation platform (CypCaps) to target cancer, notably LAPC.
|
$6.86M |
$1.00
|
|
Genefic Infusion Rx’s compounding facility indicates outsourced/pharmaceutical manufacturing capabilities (Contract Manufacturing Organizations).
|
$6.85M |
$0.06
+23.91%
|
|
Gimoti is a nasally administered small-molecule metoclopramide product that Evoke Pharma directly commercializes, representing its core pharmaceutical product line.
|
$6.82M |
$4.57
-0.41%
|
|
Cancer diagnostic initiatives place Ludwig within Biotech - Oncology as a focus area.
|
$6.79M |
$0.04
|
|
ProLectin-M/I/F constitute antiviral therapeutics targeting viral threats (COVID-19 and related viruses).
|
$6.67M |
$0.07
|
|
The company markets HOCl-based eye-care products (e.g., Lumacyn/Podiacyn), which fit the ophthalmic drugs category.
|
$6.64M |
$4.04
-6.05%
|
|
Core turnkey OEM/ODM contract manufacturing services enabling clients to outsource product development and manufacturing of biotech-nutraceutical/beauty/medical consumables.
|
$6.62M |
$0.03
|
|
Company's lead asset Annamycin is an oncology therapeutic, making Moleculin a cancer-focused biotech with direct drug development in oncology.
|
$6.52M |
$0.46
-5.78%
|
|
Directly develops and commercializes vaccines, including personalized cancer vaccines (EVX-01) and infectious disease vaccines under development.
|
$6.39M |
$5.90
-9.65%
|
|
IN8bio's core program is gamma-delta T cell therapy (INB-100/INB-200) and related iPSC-derived gamma-delta T cell products, i.e., cell therapy.
|
$6.35M |
$2.10
-7.08%
|
|
Company aims to develop Alzheimer's disease therapeutics (AL001 and ALZN002) and thus fits Alzheimer's Disease Therapeutics.
|
$6.31M |
$2.18
-5.63%
|
|
Helpson operates as a pharmaceutical manufacturer, aligning with contract manufacturing organizations that produce drugs for sale.
|
$6.17M |
$1.89
-2.07%
|
|
The therapy modulates immune cells to address hyperinflammation (cytokine storm), fitting Immunology Therapeutics as an immune-modulation modality.
|
$6.04M |
$0.57
-4.73%
|
|
HCWB is developing innovative cancer immunotherapies, placing the company in Biotech - Oncology.
|
$5.84M |
$4.06
-10.77%
|
|
Core product category aligned with pharmaceuticals/biotech (TCMP) under Large Cap Pharma.
|
$5.77M |
$1.48
-1.47%
|
|
Directly develops oncology therapeutics (antineoplastons), fitting Biotech - Oncology.
|
$5.65M |
$0.04
|
|
Company focuses on intratumoral immuno-oncology with INT230-6.00; oncology-focused biotech developing cancer therapies.
|
$5.61M |
$0.30
-17.43%
|
|
PAS-4.00 is described as an oral small-molecule therapeutic (capsules/tablets) with once-daily dosing.
|
$5.58M |
$0.75
-3.55%
|
|
VYNE focuses on immuno-inflammatory therapeutics (BET inhibitors) addressing inflammatory diseases, aligning with Biotech - Immunology Therapeutics.
|
$5.53M |
$0.33
+5.00%
|
|
Soligenix's HyBryte for CTCL is a lead oncology asset, placing the company in Biotech - Oncology.
|
$5.48M |
$1.68
-5.08%
|
|
ERNA is developing oncology-focused cell therapies (ERNA-101) for cancer, aligning with Biotech - Oncology.
|
$5.38M |
$1.29
-5.47%
|
|
IMNN-001 is a DNA-based cancer immunotherapy targeting ovarian cancer, fitting Biotech - Oncology.
|
$5.23M |
$5.37
-0.56%
|
|
BriaCell is an oncology-focused biotech developing cancer immunotherapies for metastatic breast cancer (Bria-IMT, Bria-OTS).
|
$4.69M |
$12.40
-2.21%
|
|
NurOwn is a proprietary autologous cell therapy platform (bone marrow–derived mesenchymal stem cells induced to secrete neurotrophic factors) that is the core product being developed for ALS.
|
$4.53M |
$0.69
-2.13%
|
|
Calidi Biotherapeutics is an oncology-focused biotech developing oncolytic virus platforms (NeuroNova, SuperNova, RedTail) aimed at systemic metastatic disease.
|
$4.11M |
$1.55
-1.90%
|
|
Biotech - Oncology focus in cancer diagnostics and biomarker analysis.
|
$3.94M |
$0.90
+5.28%
|
|
ADMT operates as an FDA-registered contract manufacturing facility and provides contract manufacturing services.
|
$3.87M |
$0.09
+4.12%
|
|
Company operates in neuropsychiatric drug development within the psychedelic medicine space.
|
$3.70M |
$0.93
-5.00%
|
|
The company is shifting toward outsourced OEM manufacturing services for health supplements.
|
$3.46M |
$0.09
|
|
Bezisterim (NE3107) is an orally administered small molecule therapeutic targeting inflammation-driven insulin resistance in neurodegenerative diseases, matching the Orals Small Molecule Therapeutics category.
|
$3.40M |
$1.83
-8.50%
|
|
AD04 is an oral small molecule therapeutic targeting Alcohol Use Disorder (AUD).
|
$3.15M |
$0.39
-3.34%
|
|
Lucemyra is an FDA-approved oral small-molecule therapeutic distributed by BioCorRx, aligning with the 'Oral Small Molecule Therapeutics' investable category.
|
$2.98M |
$0.45
|
|
Can-Fite's core cancer-focused assets (Namodenoson for HCC and inflammatory disease targets) place the company in Biotech - Oncology.
|
$2.66M |
$0.53
-7.02%
|
|
Processa's core pipeline comprises Next Generation Cancer therapies (NGC-Cap, NGC-Gem, NGC-Iri) targeting oncology, identifying Biotech - Oncology as the primary investable theme.
|
$2.53M |
$0.21
+10.59%
|
|
Utilizes intranasal and implantable drug delivery technologies, captured by Drug Delivery Platforms.
|
$2.52M |
$0.56
-16.31%
|
|
Core focus on endometrial stem cell research and cell-based therapies (cell therapy).
|
$2.32M |
$0.01
|
|
The company operates in biotech focused on oncology diagnostics (lung cancer detection), fitting Biotech - Oncology as a core theme.
|
$2.23M |
$2.45
-3.16%
|
|
Pipeline targets rare intestinal diseases (MVID, SBS-IF) and orphan indications, with regulatory catalyst opportunities (EMA PRIME, FDA Breakthrough) and potential non-dilutive funding.
|
$2.11M |
$2.07
-5.91%
|
|
Northstrive Biosciences is pursuing a drug delivery platform via engineered probiotic therapies (EL-22/EL-32).
|
$2.10M |
$5.31
-0.56%
|
|
Ampligen and AIM's immuno-oncology pipeline position the company as a biotech oncology-focused player.
|
$1.93M |
$2.52
-3.45%
|
|
The company is a late-stage biotech focused on rare/orphan diseases with its lead NS program, QRX003, aligning with Biotech - Rare Diseases.
|
$1.82M |
$7.20
-1.44%
|
|
Platform/portfolio emphasis on oncology applications via the Hemopurifier aligns with Biotech - Oncology themes (cancer-focused tech/drug-device interfaces).
|
$1.79M |
$0.69
-5.90%
|
|
Direct product category: Mazindol extended-release formulations developed as oral small molecule therapeutics (Quilience, Nolazol) for CNS disorders.
|
$1.73M |
$1.76
-4.35%
|
|
EB-3.00 (EVM301 series) is a lead neuropsychiatric drug development program advancing toward clinical trials.
|
$1.71M |
$0.68
-1.76%
|
|
Core oncology-focused biotech developing radiation-sensitizing cancer therapies (Ropidoxuridine) and related HDAC inhibitors.
|
$1.67M |
$3.80
+6.74%
|
|
LP-310 is an oral liposomal tacrolimus formulation (an oral small molecule) representing a direct Oral Small Molecule Therapeutics offering.
|
$1.63M |
$0.64
+16.28%
|
|
CER-T is an engineered T-cell therapy platform, a core cell-based therapy offering.
|
$1.28M |
$3.31
-20.24%
|
|
Company operates in oncology diagnostics, focusing on cancer detection tests.
|
$1.02M |
$1.60
|
|
Company's strategic pivot is toward oncology therapeutics (MpBC/TNBC) with a pan-NOS inhibitor program.
|
$979059 |
$0.02
|
|
Pipeline includes cell therapies (HemaXellarate, dCellVax, tCellVax, DuroCAR), indicating Cell Therapy manufacturing/development.
|
$703985 |
$0.02
-41.18%
|
|
APTEVO is an oncology-focused biotechnology company developing immunotherapies, aligning with Biotech - Oncology.
|
$636578 |
$1.57
-7.10%
|
|
Company's core focus is oncology with its LSD1 inhibitor seclidemstat and SP-3164 programs, placing it squarely in Biotech - Oncology.
|
$557349 |
$3.93
+0.51%
|
|
Core business: manufacturing and distribution of radiopharmaceuticals, including FDA-approved I-131 products.
|
$518499 |
$0.05
-7.75%
|
|
REVB's Gemini platform targets innate immunity/inflammation, placing the company in Immunology Therapeutics.
|
$481898 |
$1.51
+1.00%
|
|
AZD1656/AZD5658 are oral small-molecule therapeutics; CDT Equity's lead assets are repositioned pharmacological compounds.
|
$391060 |
$0.49
-7.89%
|
|
IC 100 is a humanized monoclonal IgG4 antibody targeting ASC, representing a direct Monoclonal Antibody Therapeutics product.
|
$350558 |
$0.14
-2.50%
|
|
LadRx is a biopharmaceutical company focused on oncology with LADR-based drug conjugates (aldoxorubicin) and next-generation LADR candidates.
|
$297055 |
$0.60
-20.00%
|
|
Contract manufacturing services via Cana Laboratories (5-year Pharmex agreement).
|
$229298 |
$0.00
|
|
Endari is an oral small-molecule therapeutic (L-glutamine) used to treat sickle cell disease, representing Emmaus's core product category.
|
$20252 |
$0.01
-3.83%
|
|
Polyrizon develops intranasal hydrogel barrier devices (nasal sprays) for allergy relief and viral protection, fitting the Respiratory & Nasal Care OTC category.
|
$18114 |
$1.12
-8.94%
|
|
Provides contract manufacturing services for nutraceutical products, leveraging its FDA-certified manufacturing facilities.
|
$683 |
$0.01
-4.76%
|
|
NuCana is a clinical-stage biotechnology company focused on oncology therapies, anchored by its proprietary ProTide technology and cancer drug candidates.
|
N/A |
$5.33
-10.72%
|
Showing page 8 of 8 (770 total stocks)
Loading industry metrics...
Loading comparison data...
